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Interaction of magnesium sulphate with vecuronium-induced
neuromuscular blockf
T. FUCHS-BUDER, O. H. G. WILDER-SMITH, A. BORGEAT AND E. TASSONYI
Summary
We have investigated the interaction between
magnesium sulphate 40 mg kg"1 i.v. and vecuro-
nium. First, we determined the effect of pre-
treatment with magnesium on the potency of
vecuronium using a single bolus dose-response
technique. In addition, we compared the time
course of vecuronium-induced neuromuscular
block (vecuronium 100ugkg~1) with and with-
out magnesium pretreatment. For both parts,
neuromuscular block was assessed by electro-
myography. In addition, the effect of magnesium
pretreatment on vecuronium-induced neuromus-
cular block was investigated in the context of rapid
sequence induction of anaesthesia. We found that
the neuromuscular potency of vecuronium was
increased by pretreatment with magnesium sul-
phate. The ED50 and ED90 of vecuronium with
MgSO4 were 25% lower than without MgSO4
(ED50: 21.3 vs 26.9 ug kg"1; ED90: 34.2 vs
45.7 ug kg"1; P < 0.05 for both). Mean onset time
was 147.3 (SD 22.2) s in the MgSO4-vecuronium
group vs 297.3(122) s for controls (P<0.05).
Clinical duration was prolonged (MgSO4-vecu-
ronium 43.3 (9) min vs 25.2 (5.1) min for controls;
P < 0.05). This was also true for the recovery index
(20.1 (6.6) min vs 10.6 (3.4) min; P < 0.05) and
duration to 75% recovery (63.4 (9.9) min vs
35.8 (6.9) min; P < 0.05). In the context of rapid
sequence induction, pretreatment with MgSO4
improved the intubating score of vecuronium
compared with vecuronium without MgS04, reach-
ing the same quality as that with suxamethonium
1 mg kg"1. We conclude that magnesium pretreat-
ment increased the neuromuscular potency of
vecuronium, in addition to modifying the time
course of its neuromuscular block. {Br. J. Anaesth.
1995; 74: 405-409)
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Magnesium sulphate (MgSO4) has long been used in
the treatment of pre-eclampsia and hypertension
[1,2]. In addition, MgSO4 is increasingly used for
haemodynamic control during anaesthesia [3, 4]. In
a recent study it has been demonstrated that MgSO4
as an adjuvant to general anaesthesia may modulate
nociception, probably via its interaction with
the NMDA receptor-associated calcium ionophore
[5, 6]. Thus there are several situations in which the
anaesthetist may be faced with a patient treated with
MgSO4 undergoing general anaesthesia. It is well
known that MgSO4 inhibits acetylcholine release at
motor nerve terminals [7]; consequently it may
enhance the effect of neuromuscular blockers.
Ghoneim and Long [1] found that MgSO4 poten-
tiated the neuromuscular block of depolarizing and
non-depolarizing neuromuscular blockers, as was
reported by Giesecke and colleagues [8]. Sinatra and
colleagues [9] reported on a pre-eclamptic patient in
whom the duration of vecuronium-induced neuro-
muscular block was prolonged markedly after pre-
treatment with MgSO4. Similar results have been
reported by Skaredoff, Roaf andDatta [10]. However
the interaction of MgSO4 and vecuronium bromide
has not been systematically investigated so far.
The aims of the present study were to establish a
dose—response relationship for vecuronium in
patients with and without MgSO4 pretreatment, and
to study the time course of vecuronium-induced
neuromuscular block with and without MgSO4. In
addition, we wished to see if pretreatment with
MgSO4 improved intubating conditions in a clini-
cally relevant way when using vecuronium for rapid
sequence induction.
Patients and methods
After obtaining institutional Ethics Committee ap-
proval and written informed consent, we studied 125
patients, ASA I or II, undergoing elective surgery.
Patients were excluded if they were known to have
neuromuscular disease or were receiving medications
known to influence neuromuscular function. All
patients were premedicated with midazolam 7.5 mg
orally 1 h before arrival in the operating room.
In the first part of the study, 60 patients were
allocated randomly to two groups of 30 patients each
(groups A and B) for the study of dose-response
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Figure 1 Flow diagram of rapid sequence induction study design.
relationships using a single bolus technique. Fifteen
minutes before induction of general anaesthesia,
patients in group A received MgSO4 40 mg kg"1 in
saline as an i.v. infusion over 15 min. Patients in
group B received the same volume of saline without
MgSO4. In both groups anaesthesia was induced
with fentanyl 2 ug kg"1 and thiopentone 5 mg kg"1
and maintained with 60% nitrous oxide in oxygen
via a face mask until tracheal intubation. During the
study end-tidal carbon dioxide concentration was
maintained at 4.5-5 vol % (Normocap, Datex Instru-
mentarium Corporation, Finland). Neuromuscular
transmission was assessed by electromyography
(Relaxograph, Datex Instrumentarium Corporation,
Helsinki) at the left ulnar nerve-hypothenar muscle
using transcutaneous electrodes. Measurements
commenced when anaesthesia had been induced.
The Relaxograph was set to deliver supramaximal
stimuli (0.1 ms duration) of train-of-four (TOF)
at 2 Hz every 20 s. The first of the four evoked
responses was considered the twitch height. To
minimize movement-induced changes in twitch
response during electromyography, the patient's
hand was fixed carefully to avoid electrode dis-
placement.
After stabilization of the EMG recording, one of
the following doses of vecuronium was administered:
15,25 or 35 ug kg"1 in group A (w = 10 for each dose)
and 15, 30 or 45 ug kg"1 in group B (« = 10 for each
dose). Maximum depression of the twitch response
was measured and recorded, with each patient acting
as their own control.
In the second part of the study, another 20
patients were allocated randomly to group C (n =
10) or D (n = 10) to study the influence of pre-
treatment with MgSO4 on the time constants of
vecuronium-induced neuromuscular block. Patients
in group C received MgSO4 in a manner identical to
the first part of the study, while patients in group D
received saline alone. Anaesthesia was induced with
fentanyl 2 ug kg"1 and thiopentone 5 mg kg"1, and
maintained with 1 % isofiurane, and 60 % nitrous
oxide in oxygen via a face mask. When the end-tidal
isoflurane concentration had stabilized, the Relaxo-
graph was recalibrated and the control twitch height
determined. Patients in both groups then received
vecuronium lOOugkg"1 as an i.v. bolus and the
following intervals were measured: onset time =
time between administration of vecuronium and
maximum twitch depression; clinical duration (CD)
= time between administration of vecuronium and
recovery to 25% twitch height; recovery index (RI)
= time from 25 % to 75 % twitch height recovery;
and duration 75 = time between administration of
vecuronium and recovery to 75 % twitch height.
End-tidal carbon dioxide concentration, body
temperature and isoflurane concentrations were
maintained stable during the whole study (4.5-5
vol%, 36.0-36.5 °C, 0.8-1 %, respectively). Patients
did not receive further neuromuscular blockers until
recovery to 100%+ 5% twitch height. Patients in
whom twitch height did not recover to control levels
were excluded from the study. For group C and D
patients, we also determined the plasma concen-
trations of magnesium before and 15 min after the
end of the MgSO4 or placebo infusion.
In the third part of the study we assessed the
quality of neuromuscular block in the context of
rapid sequence induction. Anaesthesia was induced
with alfentanil 10 ug kg"1, thiopentone 5 mg kg"1
and different types of neuromuscular block (fig. 1).
Forty-five patients were allocated randomly to one of
three neuromuscular block techniques (n = 15 per
group). The first group was pretreated with MgSO4
40 mg kg"1 in 100 ml of saline 15 min before rapid
sequence induction and neuromuscular block with
vecuronium 100 ug kg"1. The second group received
100 ml of saline as placebo pretreatment, again
15 min before rapid sequence induction and neuro-
muscular block with vecuronium lOOugkg"1. The
third group received suxamethonium 1 mg kg"1 for
neuromuscular block 15 min after 100 ml of saline
placebo. Sixty seconds after induction the trachea
was intubated in all patients by the same experienced
anaesthetist blinded to the treatment (fig. 1). He
assessed the intubating conditions in each patient
using the following criteria [11]: excellent = jaw
relaxed, vocal cords abducted and immobile, and no
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Table 1 Patient data (mean (SD or range))
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M/F
Age (yr)
Weight (kg)
Dose—response
MgSO4-
vecuronium
20/10
42 (19-55)
69(9)
Vecuronium
17/13
42(19-61)
71(12)
Time course
MgSO4-
vecuronium
6/4
36(18-53)
67(9)
Vecuronium
5/5
35 (24-55)
65 (17)
Intubating conditions
MgSO4-
vecuronium
8/7
43(21-64)
69(12)
Vecuronium
9/6
42(21-65)
69(11)
Suxamethonium
8/7
42 (19-63)
66(13)
diaphragmatic movement; good = jaw relaxed, vocal
cords abduced and immobile, but some diaphrag-
matic movement; poor = jaw relaxed, vocal cords
moving, and coughing; and inadequate = jaw not
relaxed and vocal cords closed.
Vecuronium dose-effect relationships for groups
A and B were determined using linear regression
analysis after log transformation of the doses and
logit transformation of the twitch responses (log dose
vs logit effect). To compare the neuromuscular
potency of vecuronium with or without pretreatment
with MgSO4 the values of ED50 and ED90 were
calculated for each group from the regression slopes.
The regression slopes were tested for parallelism by
analysis of covariance. The ED50 and ED90 values
between the two groups were compared using an
unpaired t test. For statistical comparison of the time
constants of vecuronium-induced neuromuscular
block in patients pretreated or not pretreated with
MgSO4, the Mann-Whitney U test was used.
Intubating conditions were analysed using the
Kruskall-Wallis test after assigning a numeric value
to each intubation score.
All values apart from intubating condition scores
are expressed as mean (SD) or 95 % confidence limits.
For statistical comparisons, differences were con-
sidered significant when P < 0.05.
Results
The study groups did not differ in age, sex
distribution or weight (table 1).
DOSE-RESPONSE STUDY
The regression lines of the dose-response curves did
not deviate significantly from parallelism (fig. 2).
Values for the slope, Y-intercept, coefficient of
correlation (r), ED50 and ED90 are shown in table 2.
ED50 of vecuronium was 21.3 ug kg"1 in the MgSO4
pretreated group compared with 26.9 ug kg"1 with-
out MgSO4 (P < 0.05); ED90 was 34.2 ug kg"1 in the
MgSO4 pretreated group compared with 45.7 ug kg""1
in controls (P < 0.05).
TIME COURSE OF NEUROMUSCULAR BLOCK
The onset time was 147.3 (22.2) s in the MgSO4
group compared with 297.3 (122) s in controls
(P < 0.05). The clinical duration was longer in the
MgSO4 group (43.3 (9) min) compared with controls
(25.2 (5.1) min; P < 0.05). The same was true for the
recovery index (20.1 (6.6) min vs 10.6 (3.4) min,
respectively; P < 0.05) and for recovery to 75% of
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Figure 2 Single bolus dose-response curves (log dose vs logit
effect) for vecuronium with (—) and without ( ) MgSO4.
Some individual data points are superimposed.
Table 2 Neuromuscular potency of vecuronium with and
without MgSO4 (mean (95 % confidence limits)). * P < 0.05
n
r
ED50 (jig kg"1)
ED90 (ug kg"1)
Slope
y-intercept
MgSO4—vecuronium
30
0.954
21.3*
(20.7-22.3)
34.2*
(32.1-36.5)
4.6
-6.2
Vecuronium
30
0.967
26.9
(25.8-28.3)
45.7
(43.3-^19.9)
4.1
-5.9
Table 3 Time course of neuromuscular block (mean (SD)). CD
= Clinical duration, RI = recovery index; D75 = duration until
75 % recovery of twitch height. *P < 0.05
MgSO4-vecuronium Vecuronium
Onset (s) 147.3(22.2)* 297.2(122)
CD (min) 43.3(9)* 25.2(5.1)
Rl(min) 20.1(6.6)* 10.6(3.4)
D75 (min) 63.4 (9.9)* 35.8 (6.9)
the twitch height (63.4 (9.9) min in the MgSO4
group vs 35.8 (6.9) min in controls; P < 0.05) (table
3).
Plasma magnesium concentrations are shown in
table 4; they increased from a baseline concen-
tration of 0.9(0.06) to 1.08 (0.07) mmol litre"1
15 min after the MgSO4 infusion (P < 0.05); in
controls plasma magnesium concentrations were
0.86 (0.08) mmol litre"1 before and 0.87 (0.6) mmol
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Table 4 Plasma magnesium concentrations (mmol litre"1)
(mean (SD)). Tl = Baseline concentrations before infusion; T2
= values 15 min after the end of infusion. *P < 0.05 compared
with baseline levels; \P < 0.05 compared with magnesium
group at T2.
MgSO4 (40 mg kg"1) Placebo (0.9% NaCl)
Tl
T2
0.9 (0.06)
1.08 (0.07)*
0.86 (0.08)
0.87 (0.06)t
Table 5 Intubating conditions. Criteria for intubating
conditions; excellent = jaw relaxed, vocal cords abduced and
immobile, no diaphragmatic movement; good = jaw relaxed,
vocal cords abduced and immobile, some diaphragmatic
movement; poor = jaw relaxed, vocal cords moving, coughing;
inadequate = jaw not relaxed, vocal cords closed. *P < 0.05
compared with MgSO4-vecuronium and suxamethonium
groups.
MgSO4-
vecuronium Vecuronium* Suxamethonium
Excellent 10
Good 5
Poor 0
Inadequate 0
14
1
0
0
litre"1 after the infusion (ns), respectively. The
plasma magnesium concentrations after the MgSO4
infusion were higher than after the placebo infusion
(P < 0.05). The magnesium infusions were well
tolerated, with no signs of muscular weakness. The
only discomfort described by patients was a hot flush
of the lower abdomen reported by 21 of the 55
patients.
INTUBATING CONDITIONS
Intubating conditions after pretreatment with
MgSO4 were significantly better than those obtained
with vecuronium alone, and did not differ from those
obtained with suxamethonium (table 5).
Discussion
We have shown that the neuromuscular potency of
vecuronium was increased markedly by MgSO4, the
respective ED50 and ED90 values were 20-25 % lower
in the magnesium group. For vecuronium without
MgSO4, we found an ED50 of 26.9 ug kg"1 and an
ED90 of 45.7 ug kg"1. These data are in accordance
with the results of other studies in which the single
bolus technique has been used [12, 13].
In order to quantify this interaction we used the
single bolus dose-response technique instead of the
cumulative technique described for long-acting
neuromuscular blockers [14]. The latter technique
may not be appropriate for vecuronium, as larger
potency estimates are obtained by this method than
with the single bolus technique [15]. This may arise
because the effect of the initial dose of vecuronium
has terminated before the last dose is given. For
constructing the dose-response curves we used lower
doses of vecuronium in patients pretreated with
MgSO4. This was necessary because in the pilot
dose-finding study we found that doses of vecuron-
ium as high as 45 ug kg"1 resulted in 100 % block of
neuromuscular transmission after pretreatment with
MgSO4. This would not have permitted correct
construction of a dose-response relationship.
We administered relatively low doses of MgSO4(i.e. 40 mg kg"1). We chose this dose as it is currently
used in our institution for obstetric patients. Even
such small doses of MgSO4 markedly increased the
neuromuscular potency of vecuronium. This may be
explained on the basis that the plasma concentration
of magnesium was higher 15 min after MgSO4
infusion than before, and higher than in controls.
Non-depolarizing neuromuscular blockers have both
presynaptic and postsynaptic activity at the neuro-
muscular junction [16]. Presynaptic action is thought
to occur at nicotinic receptors on the nerve terminals
that mediate autofacilitation of acetylcholine release,
while the postsynaptic action inhibits end-plate
depolarization [17]. MgSO4 has mainly presynaptic
effects by inhibiting acetylcholine release at motor
nerve terminals [7], effects which may be responsible
for the interaction with vecuronium.
In the second part of the study we examined the
influence of MgSO4 on the time course of the
neuromuscular block. We used the so-called "intu-
bating dose" of vecuronium (i.e. 100 ug kg"1)- With
this dose we found a clinical duration of action of
about 25 min. However, after pretreatment with
MgSO4 the duration of vecuronium block was nearly
doubled. The rapid recovery of neuromuscular
function after vecuronium contributes to its safety in
clinical practice. MgSO4 decreases the recovery rate
of vecuronium and considerably prolongs the time to
achieve safe extubation conditions. A longer clinical
duration of action together with slower recovery
after an intubating dose of vecuronium when used
together with magnesium results in a change in the
total duration of vecuronium-induced curarization.
In this context vecuronium no longer has the profile
of an intermediate-acting neuromuscular blocker.
The speed of onset of neuromuscular block for
vecuronium was increased markedly in the MgSO4
group; about 2 min compared with 5 min in the
controls. This is in accordance with the study of
Lampl and Dandoy [18], where the speed of onset of
atracurium was increased markedly when patients
were pretreated with MgSO4. James, Schenk and
Van Der Veen reported similar results for pan-
curonium [19]; an onset time of 68.3 s after MgSO4
pretreatment. The shorter onset time of vecuronium
after MgSO4 pretreatment may be a clinically
interesting phenomenon, because it may contribute
to improvement in intubating conditions.
To test this hypothesis, we determined the
intubating scores for rapid sequence induction with
vecuronium 100 ug kg"1 with and without MgSO4
pretreatment and compared them with those ob-
tained after suxamethonium, the gold standard for
rapid sequence induction. The intubating scores for
the group receiving vecuronium and MgSO4 pre-
treatment at 60 s after the rapid sequence induction
were better than in those receiving vecuronium
alone, and similar to the scores obtained after
suxamethonium. When using vecuronium
100 ug kg"1 without MgSO4, intubation after 60 s
was not ideal, but always possible. This may be
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explained by the findings of Donati, Meistelman and
Plaud [20] that the onset of neuromuscular block
after vecuronium is faster for the larynx than for
peripheral muscles.
The increase in plasma concentration of mag-
nesium in patients pretreated with MgSO4 was
statistically significant, but clinically safe as no
symptoms of muscle weakness were reported by the
patients. This is in accordance with the results of
Baraka and Yazigi [21] who found no clinical or
electromyographic signs of muscle weakness even at
slightly higher plasma magnesium concentrations
(1.7-2.5 mmol litre"1)- These data indicate that pre-
treatment with MgSO4 40 mg kg"1 does not induce
any degree of measurable neuromuscular block when
administered before the non-depolarizing blocker.
Thus pretreatment with MgSO4 40 mg kg"1 is safe.
MgSO4 before vecuronium improves the intubating
conditions of vecuronium for rapid sequence induc-
tion, and thus may be a useful clinical alternative
for rapid sequence induction in some patients in
whom the use of suxamethonium is contraindicated
or controversial.
We conclude that MgSO4, administered before
vecuronium, accelerated the onset of neuromuscular
block necessary for intubation of the trachea, that
MgSO4 in the presence of vecuronium intensified
and prolonged neuromuscular block, and that moni-
toring of neuromuscular function and reduction in
dose of vecuronium are required when using these
two drugs in combination.
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